ReviewNational science review2026
Multimodal pre-training models of molecular representation for drug discovery.
Review in National science review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- PMconv: How to Compare Proteomes and Metabolomes?International journal of molecular sciences · 2026Article
- Transcriptomic Traces of Noise Exposure in Hearing Loss and Systematic Identification of Biomarker Candidates at the Molecular Scale.International journal of molecular sciences · 2026Article
- CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein.Nature communications · 2026Article
- Elucidating the molecular mechanisms of paeoniflorin intervention in oral lichen planus: a computational biology and bioinformatics-based research strategy.Frontiers in bioinformatics · 2026Article
- Endometrial receptivity characteristics in patients with repeated implantation failure: a study using LASSO regression and Bayesian generalized linear model analysis.Frontiers in medicine · 2026Article
- Single-cell RNA sequencing data processing using cloud-based serverless computing.GigaByte (Hong Kong, China) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the great success of large language models in natural language processing, self-supervised pre-training models have emerged as an important technique in drug discovery. In particular, multimodal pre-training models have opened a new avenue for drug discovery. The experience and ideas from previous works can provide important reference points for further research in drug discovery. Therefore, this review summarizes the foundation of multimodal pre-training models and their progress in the field of drug discovery. We emphasize the adaptability between various modalities and network frameworks or pre-training tasks. At the same time, we summarize the difference and relevance between various modalities or pre-training models. Importantly, we identify two increasing trends that may serve as reference points for future research. Specifically, Transformers and graph neural networks are often integrated as encoders and then combined with multiple pre-training tasks to learn cross-scale molecular representation, thereby promoting the accuracy of drug discovery. In addition, molecular captions as brief biomedical text provide a bridge for collaboration between drug discovery and large language models. Finally, we discuss the challenges of multimodal pre-training models in drug discovery, and explore future opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.